Clinical Trial

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Study acronym: TroFuse-031
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
Protocol Amendment History 9 changes
notable Trial sites expanded: 73 -> 79 locations 2026-08-08
notable Trial sites expanded: 50 -> 63 locations 2026-06-24
notable Trial sites expanded: 42 -> 50 locations 2026-06-09
notable Trial sites expanded: 38 -> 42 locations 2026-05-30
notable Trial sites expanded: 30 -> 38 locations 2026-05-23
notable Trial sites expanded: 27 -> 30 locations 2026-05-16
notable Trial sites expanded: 21 -> 27 locations 2026-05-09
notable Trial sites expanded: 3 -> 21 locations 2026-05-02
critical Recruitment opened 2026-04-01
Trial Details
NCT Number NCT07419295
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Bladder Cancer
Enrollment 590 participants
Start Date 2026-04-23
Primary Completion 2029-07-27 (estimated)
Study Completion 2030-04-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-14